过去一年中添加的文章，按日期排序
2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
QJ Low, WD Looi, SJ Sukumar, Y Ang… - Annals of …, 2023 - annalsofoncology.org
264 天前 - … Conclusions: TFE3-rearranged ASPS and tRCC demonstrate a distinct TIME with
var… had received first line immunotherapy-based therapy were identified. The overall survival …
var… had received first line immunotherapy-based therapy were identified. The overall survival …
… nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
264 天前 - … to demonstrate its benefits for mccRCC. These trials, conducted with Sunitinib as the
standard treatment, … Overall survival (OS) was calculated among three groups of IO alone (…
standard treatment, … Overall survival (OS) was calculated among three groups of IO alone (…
Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
N Verma, JG Ninia, TJ Hayman, N Housri… - International Journal of …, 2023 - redjournal.org
265 天前 - … been shown to be associated with improved OS for … compare OS, progression-free
survival (PFS), local recurrence-free … Immunotherapy was given in 7 (19.4%) oligometastatic …
survival (PFS), local recurrence-free … Immunotherapy was given in 7 (19.4%) oligometastatic …
[HTML][HTML] Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy
273 天前 - … demonstrate inferior overall survival in patients with advanced nonclear cell renal
cell carcinoma … 24% of patients treated with immunotherapy-based treatment. While historical …
cell carcinoma … 24% of patients treated with immunotherapy-based treatment. While historical …
Cuproptosis-Related lncRNA Prognostic Profile, Immune microenvironment, Response and Immune-related gene prognostic index in LUAD
D Zhong - 2023 - researchsquare.com
283 天前 - … low risk had more effectiveness of immunotherapy, and we … aggressive tumor
phenotypes, have longer overall survival … Studies have shown that higher TIDE responds poorly to …
phenotypes, have longer overall survival … Studies have shown that higher TIDE responds poorly to …
Frontline IO-Based Regimens in Sarcomatoid or Rhabdoid Metastatic nccRCC.
BI Rini - Cancer Network, 2023 - go.gale.com
284 天前 - … failure, which is...a proxy for PFS [progression-free survival], … [have] been gene
expression studies that have shown … that sarcomatoid requires immunotherapy for the best …
expression studies that have shown … that sarcomatoid requires immunotherapy for the best …
[HTML][HTML] Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer
Z Gong, Y He, X Mi, C Li, X Sun, G Wang, L Li… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
286 天前 - … responsive to ICIs and had better overall survival (OS) … profiles of advanced clear
cell renal cell carcinoma cohort (… In the present study, we first demonstrated that the CCCP …
cell renal cell carcinoma cohort (… In the present study, we first demonstrated that the CCCP …
Overall Survival of Elderly Patients with Non-Small Cell Lung Cancer Treated with Programmed Death-1 (PD-1) Inhibitors and Microbiome Altering Medications: A …
V Hughes - 2023 - rave.ohiolink.edu
296 天前 - … -small cell lung cancer (NSCLC), melanoma, renal cell … lung cancer patients who
receive ICI treatments has shown to … Utilization of immunotherapy is increasing in the Medicare …
receive ICI treatments has shown to … Utilization of immunotherapy is increasing in the Medicare …
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
302 天前 - … HIF-2α inhibitor, has demonstrated antitumor activity with … Secondary endpoints
include overall survival, objective … to the primary tumor in combination with immunotherapy …
include overall survival, objective … to the primary tumor in combination with immunotherapy …
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC)(adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
302 天前 - … line treatment of ccRCC based on the CheckMate 9ER phase 3 study demonstrating
improved progression-free survival … patients who have previously received immunotherapy. …
improved progression-free survival … patients who have previously received immunotherapy. …